Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to Disease Activity Score-28
Autoimmunity, 07/23/09
Sempere-Ortells JM et al. – Study demonstrates that most of changes in regulatory T cell (Treg) parallel the intensity of inflammation, with lowest or highest values in rheumatoid arthritis (RA) patients with moderately/very active disease vs healthy controls and pts with inactive RA. The balance between these cell subsets and their antigen expression determines the inflammation levels; could be linked to the relapsing/remission periods of the disease.
Methods- Study examines the different peripheral blood (PB) Treg subsets in RA pts to test the hypothesis that changes in these cells can be linked to the degree of inflammation and relapsing/remission periods
- RA subjects (n=60) with different DAS28 and healthy controls (n=40)
- Frequencies of Treg subsets expressing characteristic membrane antigens, FoxP3 or intracellular cytokines were quantified by flow cytometry
- A decrease in % of CD4+CD25high, CD4+CD25int, CD4+CD25int/highFoxP3+, CD4+CD38+, CD4+CD62L+, CD8+CD25highCD45RA+ and CD8+CD25intCD45RA+ T cells in PB of RA pts vs healthy controls
- In addition, increased % of cells expressing membrane/intracellular regulatory antigens such as OX40 (CD134), CD45RBlow or CTLA-4 (CD152)
- A higher proportion of other T cell subsets including CD4+CTLA-4+, CD4+IL10+, CD4+CD25int IL10+, CD4+CD25int TGFβ+, CD4+CD25low TGFβ+ and CD8+CD28-
Related Articles
Determining a low disease activity threshold for decision to maintain disease modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
Arthritis Research & Therapy, 10/29/09
Relevance Score: 81%
Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics
Modern Rheumatology, 10/08/09
Relevance Score: 81%
Functional and work outcomes improve in patients with rheumatoid arthritis who receive targeted, comprehensive occupational therapy
Arthritis Care and Research, 11/05/09
Relevance Score: 80%
The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients
Rheumatology International, 10/28/09
Relevance Score: 80%
Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables
Modern Rheumatology, 10/05/09
Relevance Score: 80%
Today in Rheumatic/Autoimmune...keeping you current
Receive free subspecialty "5-minute updates" via email
Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations
Human Mutation, 12/09/09
Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid
Medical Hypotheses, 12/09/09
The idiotype connection: linking infection and multiple sclerosis
Trends in Immunology, 12/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


